GeneArt HTP Antibody Expression Service

When your research focuses on discovery and early development of a therapeutic antibody, having reliable, high quality proteins from the start can reduce the risk of late-stage failures. Our semi-automated, high-throughput platform enables reproducible and rapid production of antibodies from transiently transfected mammalian cells, while remaining flexible enough to address the needs of the rapidly evolving immunotherapy field.

As with our mid- and large-scale protein expression services, high yields are achieved with a combination of outstanding sequence optimization and high-efficiency Gibco ExpiCHO or Expi293 expression systems.

Request quote

To prevent false negatives due to poor yield, it is important to utilize a platform that maximizes expression consistently within and between production runs. Figure 1 demonstrates reproducible expression and recovery of antibodies across independent runs.

To further prevent candidate dropout later in development, expression levels should be consistent as you scale up to larger cultures. Figure 2 demonstrates consistent relative expression between small-scale, high-throughput cultures (2.5 mL) and either 200 mL or 1 L cultures.

Whether you know exactly what you need or you would like a little advice, it helps to have a technical team available to guide you through the process from quote to project delivery. Our project management team is ready to provide the level of support you need.

If you have your sequences and are ready to order, use our online quote request tool to help you provide all the information we need to prepare a prompt quote for your project.

If you still have questions, please reach out to the team directly at geneartpmo@thermofisher.com.

All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. Stunner is a trademark of Unchained Labs. FluidX is a trademark of Azenta. Octet is a trademark of Sartorius.